Buy Rating for Integra Lifesciences Amid Favorable Medicare Policy Changes

Wells Fargo analyst Vik Chopra has maintained their bullish stance on IART stock, giving a Buy rating on April 22.

Vik Chopra has given his Buy rating due to a combination of factors concerning Integra Lifesciences’s positioning and the regulatory environment. The recent proposed Local Coverage Determination (LCD) by Medicare Administrative Contractors (MACs) is viewed as neutral to slightly positive for the company. This new proposal places emphasis on higher clinical evidence for product coverage, which aligns with Integra Lifesciences’s commitment to evidence-based solutions. The company interprets this move as a positive step towards reinforcing the value of clinically supported treatments, which is likely to benefit its product portfolio.

Moreover, the proposed LCD restricts coverage to a limited number of applications and products that meet a higher standard of evidence, potentially reducing competition from less substantiated products. While the LCD excludes some of Integra’s products, such as the Meshed Bilayer Wound Matrix and SurgiMend, these exclusions are not expected to impact the company significantly since they are not used for the treatment of diabetic foot ulcers (DFUs) or venous leg ulcers (VLUs), the conditions addressed by the LCD. Integra’s key products like Omnigraft and Primatrix are well positioned to meet the new clinical evidence requirements, further justifying the Buy recommendation.

In another report released on April 22, Jefferies also maintained a Buy rating on the stock with a $50.00 price target.

IART’s price has also changed moderately for the past six months – from $35.345 to $28.410, which is a -19.62% drop .

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Integra Lifesciences (IART) Company Description:

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.